ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance t...
October 09 2020 - 6:30AM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced a poster
presentation and oral discussion at the upcoming 32nd
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics being held virtually October 24 - 25, 2020. The
presentation will highlight preclinical data in prostate cancer
cell lines that demonstrate the company’s glucocorticoid receptor
(GR) antagonist, ORIC-101, reversing GR-mediated resistance to an
androgen receptor (AR) degrader.
In the study, it was observed that upon treatment of prostate
cancer cell lines with an AR degrader, GR mRNA and protein levels
were significantly upregulated, similar to the GR upregulation seen
after dosing with enzalutamide. This GR upregulation translated
into GR activation that conferred resistance to the AR degrader,
permitting prostate cancer cells to continue to grow. ORIC-101 was
shown to completely reverse these effects and block tumor cell
growth and androgen-regulated gene expression. These data
demonstrate that GR may be a mechanism of resistance to AR
degraders and that in vitro, ORIC-101 overcomes GR-driven
resistance to AR degradation.
GR has been linked to resistance to multiple classes of cancer
therapeutics across a variety of solid tumors. ORIC-101 is
currently in two separate Phase 1b trials of ORIC-101 in
combination with Xtandi (enzalutamide) in metastatic prostate
cancer and Abraxane (nab-paclitaxel) in advanced or metastatic
solid tumors. ORIC expects to report interim data from one of the
trials in the first half of 2021 and from the other trial in the
second half of 2021.
Details of the poster presentation are as follows:
Title: ORIC-101 Overcomes GR-driven Resistance
to AR Degradation in Castration-Resistant Prostate Cancer
ModelsDate: October 25, 2020;
2:30 p.m. CESTSession: Poster Discussion
SessionTopic: Approaches to Overcoming Therapeutic
Resistance Abstract: PD-050
About ORIC Pharmaceuticals, Inc.ORIC
Pharmaceuticals is a clinical stage biopharmaceutical company
dedicated to improving patients’ lives
by Overcoming Resistance In Cancer. ORIC’s
lead product candidate, ORIC-101, is a potent and selective small
molecule antagonist of the glucocorticoid receptor, which has been
linked to resistance to multiple classes of cancer therapeutics
across a variety of solid tumors. ORIC-101 is currently in two
separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi
(enzalutamide) in metastatic prostate cancer and (2) Abraxane
(nab-paclitaxel) in advanced or metastatic solid
tumors. ORIC’s other product candidates include (1) ORIC-533,
an orally bioavailable small molecule inhibitor of CD73, a key node
in the adenosine pathway believed to play a central role in
resistance to chemotherapy- and immunotherapy-based treatment
regimens, and (2) ORIC-944, an allosteric inhibitor of the polycomb
repressive complex 2 (PRC2) via the EED subunit, being developed
for prostate cancer. Beyond these three product candidates, ORIC is
also developing multiple precision medicines targeting other
hallmark cancer resistance mechanisms. ORIC has offices in South
San Francisco and San Diego, California. For more information,
please go to www.oricpharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about ORIC as that term is defined in Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, statements regarding ORIC’s
development plans; the ability of ORIC-101 to overcome resistance
in cancer models; plans underlying ORIC-101 clinical trials and
development; plans to report interim data from the two ongoing
clinical trials of ORIC-101; and the potential advantages of ORIC’s
product candidates. Words such as “believes,” “anticipates,”
“plans,” “expects,” “intends,” “will,” “goal,” “potential” and
similar expressions are intended to identify forward-looking
statements. The forward-looking statements contained herein are
based upon ORIC’s current expectations and involve assumptions that
may never materialize or may prove to be incorrect. Actual results
could differ materially from those projected in any forward-looking
statements due to numerous risks and uncertainties, including but
not limited to: risks associated with the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics and operating as an early clinical
stage company; ORIC’s ability to develop, initiate or complete
preclinical studies and clinical trials for, obtain approvals for
and commercialize any of its product candidates; changes in ORIC’s
plans to develop and commercialize its product candidates; the
potential for clinical trials of ORIC-101 or any future clinical
trials of other product candidates to differ from preclinical,
preliminary or expected results; negative impacts of the COVID-19
pandemic on ORIC’s operations, including clinical trials; ORIC’s
ability to raise any additional funding it will need to continue to
pursue its business and product development plans; regulatory
developments in the United States and foreign countries; ORIC’s
reliance on third parties, including contract manufacturers and
contract research organizations; ORIC’s ability to obtain and
maintain intellectual property protection for its product
candidates; the loss of key scientific or management personnel;
competition in the industry in which ORIC operates; general
economic and market conditions; and other risks. Information
regarding the foregoing and additional risks may be found in the
section entitled “Risk Factors” in ORIC’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (the “SEC”)
on August 5, 2020, and ORIC’s future reports to be filed with the
SEC. These forward-looking statements are made as of the date of
this press release, and ORIC assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Contact:Dominic Piscitelli, Chief Financial
Officer dominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jul 2023 to Jul 2024